Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 11/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417004 | 1.00 | LOXL2 (0.42) | LOXL2RXRARXRBRXRGAR | |
| SCHEMBL12497799 | 0.86 | RXRA (0.52) | RXRARXRBRXRGARNSD2 | |
| SCHEMBL14697183 | 0.82 | RXRA (0.42) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL31435395 | 0.82 | RXRA (0.42) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL25185937 | 0.82 | RXRA (0.42) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL24108442 | 0.82 | RXRA (0.42) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL16691050 | 0.82 | AR (0.48) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL10703186 | 0.82 | AR (0.51) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL28812617 | 0.79 | RXRA (0.40) | RXRARXRBRXRGARSLC22A12 | |
| SCHEMBL15716249 | 0.78 | AR (0.43) | RXRARXRBRXRGARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137513-B | Pyrimidine derivatives | ASKA 制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| EP-3372589-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2021-10-20 | — | — | EP | disclosed |
| US-10710967-B2 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| EP-3372589-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | CXCR1, PTGS1, P2RY1 | LOXL2 3013/4885RXRA 399/4885RXRB 461/4885 |
| US-10710967-B2 | Pyrimidine derivative | CXCR1, PTGS1, P2RY1 | LOXL2 3013/4885RXRA 399/4885RXRB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.